4//SEC Filing
McClung David Mark 4
Accession 0001209191-23-016395
CIK 0001001233other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 5:09 PM ET
Size
11.2 KB
Accession
0001209191-23-016395
Insider Transaction Report
Form 4
McClung David Mark
EVP Chief Business Officer
Transactions
- Tax Payment
Common Stock
2023-02-25$2.66/sh−9,745$25,922→ 224,774 total - Award
Common Stock
2023-02-24+56,250→ 234,519 total - Award
Stock Option (Right to Buy)
2023-02-24+262,500→ 262,500 totalExercise: $2.66Exp: 2033-02-23→ Common Stock (262,500 underlying)
Footnotes (5)
- [F1]Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP.
- [F2]Includes 2,453 shares acquired on November 30, 2022 under the Issuer's 2020 Employee Stock Purchase Plan.
- [F3]Represents shares underlying the portions of RSU grants that vested on February 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2023 of $2.66/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
- [F4]Includes: (a) 8,722 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2021 RSU grant and 13,336 shares subject to such RSU grant that will vest in one final installment on February 25, 2024, (b) 9,715 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 44,550 shares will vest in 8 successive equal quarterly installments thereafter and (c) 33,430 shares subject to the Reporting Person's June 25, 2020 RSU grant that will vest in one final installment on June 25, 2023. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
- [F5]One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Documents
Issuer
SANGAMO THERAPEUTICS, INC
CIK 0001001233
Entity typeother
Related Parties
1- filerCIK 0001811505
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 5:09 PM ET
- Size
- 11.2 KB